natgillin/translations-raw huggingface dataset:
One month after primary vaccination at least 98.7% of subjects were seroprotected against diphtheria, tetanus and poliovirus types 1 and 2; at least 90.9% had seroprotective antibody levels against the hepatitis B, PRP and poliovirus type 3 antigens; and all subjects were seropositive for antibodies against FHA and PRN while 94.9% were seropositive for anti-PT antibodies. 
En mesec po primarnem cepljenju je bilo vsaj 98,7 % preiskovancev serološko zaščitenih pred davico, tetanusom in poliovirusom tipov 1 in 2; vsaj 90,9 % jih je imelo serološko zaščitno koncentracijo protiteles proti antigenom hepatitisa B, PRP in poliovirusu tipa 3; in vsi preiskovanci so bili seropozitivni za protitelesa proti FHA in PRN, medtem kot je bilo 94,9 % seropozitivnih za protitelesa proti PT.
0.5 ml of suspension in a pre-filled syringe (type I glass) with plunger stopper (butyl). 
0,5 ml suspenzije v napolnjeni injekcijski brizgi (steklo tipa I) z zamaškom iz butilne gume.
The clinical protection of the pertussis component of Infanrix (DTPa), against WHO-defined typical pertussis (≥ 21 days of paroxysmal cough) was demonstrated after 3-dose primary immunisation in the studies tabulated below: 
Klinična zaščita s sestavino pertusis cepiva Infanrix (DTPa) proti značilnemu oslovskemu kašlju v skladu z definicijo Svetovne zdravstvene organizacije (napadi kašlja, ki trajajo ≥ 21 dni) je bila dokazana po primarni imunizaciji s 3 odmerki v študijah, prikazanih v spodnji preglednici:
Name and address of the manufacturers of the biological active substances 
Ime in naslov izdelovalcev biološke zdravilne učinkovine (učinkovin)
The pre-filled syringe can be supplied with either a ceramic coated treatment (CCT) of the luer tip or with a plastic rigid tip cap (PRTC) luer lock adaptor. 
Napolnjena injekcijska brizga je lahko opremljena bodisi s keramičnim kritjem (CCT, ceramic coated treatment) konice luer bodisi z nastavkom luer lock s plastičnim togim pokrovčkom konice (PRTC, plastic rigid tip cap).
Results of ongoing routine national surveillance in Italy demonstrate that Infanrix hexa is effective in controlling Hib disease in infants when the vaccine is administered according to the 3 and 5 months primary vaccination schedule, with a booster dose administered at approximately 11 months. 
Rezultati potekajočega rutinskega nacionalnega spremljanja v Italiji kažejo, da je cepivo Infanrix hexa učinkovito pri obvladovanju bolezni Hib pri dojenčkih, če je cepivo uporabljeno po 3- in 5-mesečnem razporedu primarnega cepljenja in z obnovitvenim odmerkom po približno 11 mesecih.
Bleeding or bruising more easily than normal (thrombocytopenia) has been reported with hepatitis B vaccines. 
Krvavitve ali hitrejši pojav modric od običajnega (trombocitopenija) so bili poročani v povezavi s cepivom proti hepatitisu B.
Fever >39.5°C, injection site reactions, 
Pogosti zvišana telesna temperatura > 39,5 °C, reakcije na mestu injiciranja, vključno z zatrdlino,
According to different studies, immune response to the PRP antigen of Infanrix hexa after 2 doses given at 2 and 4 months of age will vary if co-administered with a tetanus toxoid conjugate vaccine. 
Različne študije kažejo, da se imunski odziv na antigen PRP v cepivu Infanrix hexa po 2 odmerkih, uporabljenih 2. in 4. mesec, razlikuje, če je cepivo uporabljeno sočasno s konjugiranim tetanusnim toksoidnim cepivom.
• Hepatitis B: is caused by the hepatitis B virus. 
• Hepatitis B: povzroča ga virus hepatitisa B, ki povzroči oteklino jeter (vnetje).
As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine. 
Kot pri vseh drugih cepivih, ki jih injiciramo, morate imeti na voljo ustrezno zdravljenje in nadzor v redkih primerih anafilaktične reakcije, ki lahko sledi cepljenju.
Locally established immunoprophylactic measures against hepatitis B should be maintained. 
Treba je upoštevati lokalno uveljavljena priporočila imunoprofilakse proti hepatitisu B. Pediatrična populacija
Signs of an allergic reaction may include itchy skin, rash, shortness of breath and swelling of the face or tongue. 
Znaki preobčutljivostne reakcije lahko vključujejo srbečo kožo, kožni izpuščaj, zasoplost in zatekanje obraza ali jezika;
Italy 2,4,6 months 84% In a follow-up of the same cohort, the efficacy was confirmed up to 60 months after completion of primary vaccination without administration of a booster dose of pertussis. 
84 % Pri spremljanju iste kohorte je bila učinkovitost potrjena do 60. meseca po popolnem osnovnem cepljenju brez dajanja obnovitvenega odmerka proti oslovskemu kašlju.
Serological correlates of protection have been established for diphtheria, tetanus, polio, Hepatitis B and Hib. 
Serološki korelati zaščite so bili ugotovljeni za davico, tetanus, polio, hepatitis B in Hib.
Do not administer the vaccine intravascularly or intradermally. 
Cepiva ne dajemo intravaskularno ali intradermalno.
Over a seven year follow-up period, the effectiveness of the Hib components of two hexavalent vaccines, of which one was Infanrix hexa, was 89.6% for a full primary series and 100% for a full primary series plus booster dose (irrespective of the Hib vaccine used for priming). 
Po sedmih letih spremljanja je bila učinkovitost komponent proti Hib dveh šestvalentnih cepiv, od katerih je bilo eno cepivo Infanrix hexa, po popolnem osnovnem cepljenju 89,6 %, po popolnem osnovnem cepljenju in cepljenju z obnovitvenim odmerkom pa 100 % (neodvisno od izbire cepiva Hib za osnovno cepljenje).
The virus is found in body fluids such as in the vagina, blood, semen or spit (saliva) of infected people. 
Pri okuženih ljudeh se virus nahaja v telesnih tekočinah, kot so kri, sperma ali izpljunek (slina) ter v nožnici.
As with other vaccines, administration of Infanrix hexa should be postponed in subjects suffering from acute severe febrile illness. 
Kot pri cepljenju z drugimi cepivi, moramo cepljenje s cepivom Infanrix hexa odložiti pri otrocih, ki prebolevajo hudo akutno vročinsko bolezen.
Hepatitis B surface antigen (HBs)2,3 
8 mikrogramov površinski antigen virusa hepatitisa B (HBs)2,3
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 1 dose 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 1 odmerek
(≥1/10,000 to <1/1,000) 
(≥ 1/10.000 do < 1/1.000)
At least 25.4% (anti-PT), 97.5% (anti-FHA) and 87.0% (anti-PRN) of children were seropositive against the pertussis components. 
Proti komponentam oslovskega kašlja je bilo seropozitivnih vsaj 25,4 % (anti-PT), 97,5 % (anti-FHA) in 87,0 % (anti-PRN) otrok.
DTPa-HBV-IPV suspension: sodium chloride (NaCl), medium 199 containing principally amino acids, mineral salts, vitamins and water for injections 
DTPa-HBV-IPV suspenzija: natrijev klorid (NaCl), medij 199, ki vsebuje predvsem aminokisline, mineralne soli, vitamine in voda za injekcije
months N= 1693 (6 studies) 
mesecev N = 1693 (6 študij)
As Infanrix hexa is not intended for use in adults, adequate human data on use during pregnancy or lactation and adequate animal reproduction studies are not available. 
4.6 Plodnost, nosečnost in dojenje Ker cepivo Infanrix hexa ni namenjeno uporabi pri odraslih, ni podatkov o uporabi med nosečnostjo in dojenjem, prav tako ni na voljo ustreznih študij o vplivu na razmnoževanje pri živalih.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety, specific toxicity, repeated dose toxicity and compatibility of ingredients. 
Predklinični podatki na osnovi običajnih študij varnosti, specifične toksičnosti, toksičnosti pri ponavljajočih se odmerkih in kompatibilnosti sestavin ne kažejo posebnega tveganja za človeka.
Read the package leaflet before use Intramuscular use Shake well before use 
Pred uporabo preberite priloženo navodilo za intramuskularno uporabo Pred uporabo dobro pretresite
Infanrix hexa has been administered to more than 1000 preterm infants (born after a gestation period of 24 to 36 weeks) in primary vaccination studies and in more than 200 preterm infants as a booster dose in the second year of life. 
Cepivo Infanrix hexa je bilo uporabljeno pri več kot 1000 nedonošenčkih (rojenih po gestacijski starosti od 24 do 36 tednov) v študijah primarnega cepljenja in pri več kot 200 nedonošenčkih kot obnovitveni odmerek v drugem letu življenja.
weeks N= 265 (1 study) 
tednov N = 265 (1 študija)
Pertactin (PRN)1 
25 mikrogramov pertaktin (PRN)1
Infanrix hexa is contraindicated if the infant or toddlers has experienced an encephalopathy of unknown aetiology, occurring within 7 days following previous vaccination with pertussis containing vaccine. 
Uporaba cepiva Infanrix hexa je kontraindicirana, če je dojenček ali otrok prebolel encefalopatijo neznanega vzroka, ki se je pojavila v sedmih dneh po predhodnem cepljenju s cepivom, ki je vsebovalo tudi komponento proti oslovskemu kašlju.
• Infanrix hexa helps your child's body make its own protection (antibodies). 
Kako cepivo Infanrix hexa deluje • Cepivo Infanrix Hexa pomaga telesu vašega otroka ustvariti lastno zaščito (protitelesa).
The immunogenicity of Infanrix hexa was evaluated across three studies including approximately 300 preterm infants (born after a gestation period of 24 to 36 weeks) following a 3-dose primary vaccination course at 2, 4 and 6 months of age. 
Imunogenost cepiva Infanrix hexa so ocenili v treh študijah, ki so zajele približno 300 nedonošenčkov (rojenih po gestacijski starosti od 24 do 36 tednov), po primarnem cepljenju s tremi odmerki v starosti 2, 4 in 6 mesecev.
• if your child tends to have fits when they have a fever, or if there is a history of this in the family. 
• če je vaš otrok nagnjen h krčem, ko ima zvišano telesno temperaturo ali pa so se ti pojavljali v družini;
Powder in a vial (type I glass) with a stopper (butyl). 
Prašek v viali (steklo tipa I) z zamaškom iz butilne gume.
Infanrix hexa, Powder and suspension for suspension for injection. 
Infanrix hexa, prašek in suspenzija za suspenzijo za injiciranje.
As has been observed for DTPa and DTPa-containing combinations, an increase in local reactogenicity and fever was reported after booster vaccination with Infanrix hexa with respect to the primary course. 
Kot pri DTPa-cepivu in kombiniranih cepivih, ki vsebujejo DTPa, so poročali o povečanem pojavu lokalnih reakcij in zvišane telesne temperature po aplikaciji obnovitvenega odmerka cepiva Infanrix hexa v primerjavi z osnovnim cepljenjem.
Infanrix hexa will not prevent disease caused by pathogens other than Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, hepatitis B virus, poliovirus or Haemophilus influenzae type b. However, it can be expected that hepatitis D will be prevented by immunisation as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection. 
Cepivo Infanrix hexa ne prepreči bolezni, ki jih povzročijo drugi patogeni, ne pa Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, virus hepatitisa B, poliovirus ali Haemophilus influenzae tipa b. Vendar je mogoče pričakovati, da bo cepljenje preprečilo hepatitis D, kajti hepatitis D (ki ga povzroča agens delta) se ne pojavi, če ni okužbe s hepatitisom B.
Less commonly, the bacteria can also infect the blood, heart, lungs, bones, joints, and tissues of the eyes and mouth. 
Manj pogosto povzroči tudi okužbo krvi, srca, pljuč, kosti, sklepov in očesnih in ustnih sluznic.
Your doctor may ask you to give your child a medicine that lowers fever (such as paracetamol) before or immediately after Infanrix hexa is given. 
Zdravnik vam bo morda naročil, da otroku pred cepljenjem ali takoj po cepljenju s cepivom Infanrix hexa date zdravilo za znižanje zvišane telesne temperature (vročine) (kot npr. paracetamol).
• Both components are mixed together just before your child receives the injection. 
• Tik preden bo vaš otrok prejel odmerek, bodo obe komponenti pomešali skupaj.
• Not all pack sizes may be marketed. 
• Na trgu morda ni vseh navedenih pakiranj.
8 D-antigen unit type 3 (Saukett strain)4 
8 D-antigenskih enot tip 3 (sev Saukett) 4
The following drug-related adverse reactions were reported in clinical studies (data from more than 16,000 subjects) and during post-marketing surveillance. 
V kliničnih študijah (podatki pridobljeni pri več kot 16.000 preiskovancih) in v obdobju trženja so poročali o naslednjih s cepivom povezanih neželenih učinkih.
Country Schedule Vaccine efficacy 
Država Shema cepljenja
PARTICULARS TO APPEAR ON THE OUTER PACKAGING 1 VIAL AND 1 PRE-FILLED SYRINGE WITHOUT NEEDLE 10 VIALS AND 10 PRE-FILLED SYRINGES WITHOUT NEEDLES 1 VIAL AND 1 PRE-FILLED SYRINGE WITH 2 NEEDLES 10 VIALS AND 10 PRE-FILLED SYRINGES WITH 20 NEEDLES 
1 VIALA IN 1 NAPOLNJENA INJEKCIJSKA BRIZGA BREZ INJEKCIJSKE IGLE 10 VIAL IN 10 NAPOLNJENIH INJEKCIJSKIH BRIZG BREZ IGEL 1 VIALA IN 1 NAPOLNJENA INJEKCIJSKA BRIZGA Z 2 IGLAMA 10 VIAL IN 10 NAPOLNJENIH INJEKCIJSKIH BRIZG Z 20 IGLAMI
Powder and suspension for suspension for injection. 
Prašek in suspenzija za suspenzijo za injiciranje.
The lyophilised Haemophilus influenzae type b (Hib) component is a white powder. 
Komponenta Haemophilus influenzae tipa b (Hib) je bel liofiliziran prašek.
Other medicines and Infanrix hexa 
Druga zdravila in cepivo Infanrix hexa
Whooping cough can also cause ear infections, chest infections (bronchitis) which may last a long time, lung infections (pneumonia), fits, brain damage and even death. 
Oslovski kašelj lahko povzroči vnetje ušes, vnetje v prsnem košu (bronhitis), ki je lahko dolgotrajno, vnetje pljuč (pljučnico), krče, poškodbe možganov in celo smrt.
(≥1/1,000 to <1/100) 
(≥ 1/1.000 do < 1/100)
months N= 1055 (6 studies) 
mesecev N = 1055 (6 študij)
• This vaccine has been prescribed for your child only. 
• Cepivo je bilo predpisano vašemu otroku in ga ne smete dajati drugim.
The other ingredients are: 
Aktivne sestavine so:
In extremely rare cases the following side effects have been reported with hepatitis B vaccine: paralysis, numbness or weakness of the arms and legs (neuropathy), inflammation of some nerves, possibly with pins and needles or loss of feeling or normal movement (Guillain-Barré syndrome), swelling or infection of the brain (encephalopathy, encephalitis), infection around the brain (meningitis). 
V zelo redkih primerih so bili v povezavi s cepivom proti hepatitisu B poročani naslednji neželeni učinki: paraliza, otrplost ali šibkost rok in nog (nevropatija), vnetje nekaterih živcev, lahko z mravlinčenjem ali izgubo občutka ali normalnega gibanja (Guillain-Barrejev sindrom), oteklost ali okužba možganov (encefalopatija, encefalitis), okužba okrog možganov (meningitis).
Holding the syringe barrel in one hand (avoid holding the syringe plunger), unscrew the syringe cap by twisting it anticlockwise. 
Z eno roko držite valj brizge (ne bata brizge) in odvijte pokrovček brizge, tako da ga zasučete v smeri, nasprotni urnemu kazalcu.
Medium 199 containing principally amino acids, mineral salts, vitamins Water for injections 
brezvodna laktoza natrijev klorid medij 199, ki vsebuje predvsem aminokisline, mineralne soli, vitamine voda za injekcije
• There should be an interval of at least 2 months between primary doses. 
• Med primarnima odmerkoma morata miniti vsaj 2 meseca.
Very common (these may occur with more than 1 in 10 doses of the vaccine): feeling tired, loss of appetite, high temperature of 38°C or higher, swelling, pain, redness where the injection site was given, unusual crying, feeling irritable or restless. 
Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 odmerkov cepiva): občutek utrujenosti, izguba apetita, zvišana telesna temperatura 38 °C ali več, oteklost, bolečina, pordelost na mestu injiciranja, nenavadno jokanje, občutek razdražljivosti ali nemirnosti.
Other side effects include: 
Ostali neželeni učinki so:
The effectiveness of the Hib component of Infanrix hexa was investigated via an extensive postmarketing surveillance study conducted in Germany. 
Obširna študija postmarketinškega spremljanja učinkovitosti komponente cepiva Infanrix hexa proti Hib je bila izvedena v Nemčiji.
HIV infection is not considered as a contraindication. 
Okužbe z virusom humane imunske pomanjkljivosti (HIV) ne prištevamo h kontraindikacijam.
Poliovirus (inactivated) (IPV) type 1 (Mahoney strain)4 
10 mikrogramov poliovirus (inaktivirani) (IPV) tip 1 (sev Mahoney) 4
N = number of subjects * Samples tested by ELISA to have anti-diphtheria antibody concentrations < 0.1 IU/ml were re-tested using Vero-cell neutralisation assay (seroprotection cut-off ≥ 0.016 IU/ml): 96.5% of the subjects were seroprotected § Number of subjects from 2 clinical studies 
N = število preiskovancev * Vzorce, ki so imeli z ELISA koncentracijo protiteles proti davici < 0,1 i.e./ml, so ponovno testirali z uporabo nevtralizacijskega preizkusa z Vero-celicami (mejna vrednost serološke zaščite
Data from one clinical study indicate that when Infanrix hexa is co-administered with MMRV vaccine, the rate of febrile reactions is higher compared to that occurring following the administration of Infanrix hexa alone and similar to that occurring following the administration of MMRV vaccine alone (see sections 4.4 and 4.8). 
Podatki ene klinične študije kažejo, da je delež febrilnih reakcij po uporabi cepiva Infanrix hexa skupaj s cepivom MMRV večji, kot če je cepivo Infanrix hexa uporabljeno samo, in podoben tistemu po uporabi cepiva MMRV samega (glejte poglavji 4.4 in 4.8).
Common (these may occur with up to 1 in 10 doses of the vaccine): diarrhoea, being sick (vomiting), high temperature of more than 39.5°C, swelling larger than 5 cm or hard lump where the injection was given, feeling nervous. 
Pogosti (pojavijo se lahko pri največ 1 od 10 odmerkov cepiva): driska, bruhanje, zvišana telesna temperatura nad 39,5 °C, več kot 5 cm velika oteklina ali trda bula na mestu injiciranja, občutek živčnosti.
Nervousness 
vznemirjenost
MARKETING AUTHORISATION HOLDER GlaxoSmithKline Biologicals s.a. 
IMETNIK DOVOLJENJA ZA PROMET GlaxoSmithKline Biologicals s.a.
• if your child has had an allergic reaction to any vaccine against diphtheria, tetanus, whooping cough, hepatitis B, polio or Haemophilus influenzae type b. 
• če je kdaj imel alergijsko reakcijo na katerokoli cepivo proti davici, tetanusu, oslovskemu kašlju, hepatitisu B, otroški paralizi ali Haemophilus influenzae tipa b;
Hib powder: lactose anhydrous 
Hib prašek: brezvodna laktoza
Powder and suspension for suspension for injection in a pre-filled syringe Vial: powder 
prašek in suspenzija za suspenzijo za injiciranje v napolnjeni injekcijski brizgi viala: prašek napolnjena injekcijska brizga: suspenzija
METHOD AND ROUTE(S) OF ADMINISTRATION Read the package leaflet before use Intramuscular use 
POSTOPEK IN POT(I) UPORABE ZDRAVILA Pred uporabo preberite priloženo navodilo za intramuskularno uporabo
Wounds that are more likely to get tetanus infection are burns, fractures, deep wounds or wounds that have soil, dust, horse manure or wood splinters in them. 
Rane, ki se še posebno rade okužijo s tetanusom, so opekline, zlomi, globoke rane ali rane onesnažene z zemljo,
Bordetella pertussis antigens Pertussis toxoid (PT)1 
antigeni Bordetella pertussis toksoid Bordetella pertussis (PT)1
Talk to your doctor or pharmacist before your child is given Infanrix hexa: 
se posvetujte z zdravnikom ali s farmacevtom, preden bo vaš otrok cepljen s cepivom Infanrix hexa.
The physician should be aware that the rate of febrile reactions is higher when Infanrix hexa is coadministered with a pneumococcal conjugate vaccine (PCV7, PCV10, PCV13), or with a measlesmumps-rubella-varicella (MMRV) vaccine, compared to that occurring following the administration of Infanrix hexa alone. 
Zdravnik se mora zavedati, da je delež febrilnih reakcij večji, če je cepivo Infanrix hexa uporabljeno sočasno s konjugiranim pnevmokoknim cepivom (PCV7, PCV10, PCV13) ali s cepivom MMRV
Filamentous Haemagglutinin (FHA)1 
25 mikrogramov filamentozni hemaglutinin (FHA)1
How the vaccine is given 
Kako bo vaš otrok prejel cepivo
Rash, Angioedema2 
Redki izpuščaj, angioedem2
The coughing often has a “whooping” sound. 
Kašelj ima značilen zvok, ki zveni kot oslovski glas.
Analysis of postmarketing reporting rates suggests a potential increased risk of convulsions (with or without fever) and HHE when comparing groups which reported use of Infanrix hexa with Prevenar 13 to those which reported use of Infanrix hexa alone. 
Analiza pogostnosti poročanja v obdobju trženja nakazuje potencialno povečano tveganje za konvulzije (z ali brez vročine) in hipotonično-hiporesponzivno epizodo pri skupini, ki je prejela cepivo Infanrix hexa in cepivo Prevenar 13 v primerjavi s skupino, ki je prejela le cepivo Infanrix hexa.
Data from clinical studies show similar incidences of fever when Infanrix hexa is co-administered with other pneumococcal saccharide conjugated vaccine. 
Podatki iz kliničnih študij kažejo podobno pojavnost zvišane telesne temperature, če je cepivo Infanrix hexa uporabljeno skupaj s konjugiranim pnevomokoknim polisaharidnim cepivom.
Results of long term follow-up in Sweden demonstrate that acellular pertussis vaccines are efficacious in infants when administered according to the 3 and 5 months primary vaccination schedule, with a booster dose administered at approximately 12 months. 
Pri dolgotrajnem spremljanju cepiv na Švedskem se je izkazalo, da so brezcelična cepiva proti oslovskemu kašlju učinkovita, če so bili otroci osnovno cepljeni po shemi 3. in 5. mesec starosti ter so prejeli obnovitveni odmerek pri približno 12 mesecih starosti.
Fever of greater than 39.5°C was reported in 18% of children receiving Infanrix hexa with MMRV vaccine, as compared to 3.3% of children receiving Infanrix hexa alone and 19.3% of children receiving MMRV alone (see sections 4.4 and 4.5). 
Zvišano telesno temperaturo nad 39,5 °C so zabeležili pri 18 % otrok, ki so dobili cepivo Infanrix hexa skupaj s cepivom MMRV, pri 3,3 % otrok, ki so dobili cepivo Infanrix hexa samo, in pri 19,3 % otrok, ki so dobili cepivo MMRV samo (glejte poglavji 4.4 in 4.5).
Infanrix hexa can be given concomitantly with pneumococcal conjugate vaccines (PCV7, PCV10 and PCV13), meningococcal serogroup C conjugate vaccine (CRM197 and TT conjugates), meningococcal serogroups A, C, W-135 and Y conjugate vaccine (TT conjugate), meningococcal serogroup B vaccine (MenB), oral rotavirus vaccine and measles-mumps-rubella-varicella (MMRV) vaccine. 
PCV10 in PCV13), konjugiranim cepivom proti meningokokom serološke skupine C (konjugati CRM 197 in TT), konjugiranim cepivom proti meningokokom seroloških skupin A, C, W-135 in Y (konjugat TT), cepivom proti meningokokom seroskupine B (MenB) peroralnim cepivom proti rotavirusom in cepivom MMRV (cepivo proti ošpicam-mumpsu-rdečkam-noricam).
Infanrix hexa is indicated for primary and booster vaccination of infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b. 
Cepivo Infanrix hexa je indicirano za osnovno in obnovitveno cepljenje dojenčkov in otrok proti davici, tetanusu, oslovskemu kašlju, hepatitisu B, otroški ohromelosti in boleznim, ki jih povzroča Haemophilus influenzae tipa b.
Upon storage, a clear liquid and white deposit may be observed in the pre-filled syringe containing the DTPa-HBV-IPV suspension. 
Med shranjevanjem se lahko v napolnjeni injekcijski brizgi, ki vsebuje suspenzijo DTPa-HBV-IPV, pojavi bistra tekočina in bela usedlina.
In a clinical study in which some of the vaccinees received a booster dose of Infanrix hexa concomitantly with measles-mumps-rubella-varicella (MMRV) vaccine, fever ≥ 38.0°C was reported in 76.6% of children receiving MMRV vaccine and Infanrix hexa at the same time, as compared to 48% of children receiving Infanrix hexa alone and 74.7% of children receiving MMRV vaccine alone. 
V klinični študiji, v kateri so nekateri cepljeni otroci dobili obnovitveni odmerek cepiva Infanrix hexa sočasno s cepivom MMRV (cepivo proti ošpicam-mumpsu-rdečkam-noricam), so zvišano telesno temperaturo ≥ 38,0 °C zabeležili pri 76,6 % otrok, ki so hkrati prejeli cepivi MMRV in Infanrix hexa;
months N= 196 (2 studies) 
mesece N = 196 (2 študiji)